© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
BrainsWay Ltd. (BWAY) stock surged +0.87%, trading at $15.09 on NASDAQ, up from the previous close of $14.96. The stock opened at $14.96, fluctuating between $14.79 and $15.22 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 09, 2026 | 14.86 | 15.22 | 14.79 | 15.09 | 68.64K |
| Jul 08, 2026 | 14.95 | 15.31 | 14.85 | 14.96 | 75.66K |
| Jul 07, 2026 | 15.65 | 15.68 | 14.65 | 14.98 | 72.63K |
| Jul 06, 2026 | 15.51 | 16.26 | 15.48 | 16.02 | 138.54K |
| Jul 02, 2026 | 15.36 | 15.75 | 15.10 | 15.19 | 80.89K |
| Jul 01, 2026 | 15.51 | 15.70 | 15.06 | 15.29 | 58.71K |
| Jun 30, 2026 | 15.17 | 15.69 | 15.17 | 15.51 | 68.18K |
| Jun 29, 2026 | 14.90 | 15.33 | 14.52 | 15.17 | 113.04K |
| Jun 26, 2026 | 14.37 | 14.94 | 14.33 | 14.48 | 69.34K |
| Jun 25, 2026 | 14.41 | 14.85 | 14.30 | 14.54 | 53.46K |
| Jun 24, 2026 | 14.39 | 14.66 | 14.17 | 14.40 | 54.9K |
| Jun 23, 2026 | 14.00 | 14.59 | 13.88 | 14.39 | 70.61K |
| Jun 22, 2026 | 14.99 | 15.00 | 14.33 | 14.38 | 116.92K |
| Jun 18, 2026 | 14.52 | 15.05 | 14.35 | 14.89 | 254.2K |
| Jun 17, 2026 | 14.13 | 14.61 | 14.00 | 14.41 | 78.97K |
| Jun 16, 2026 | 14.33 | 14.33 | 14.01 | 14.13 | 72.77K |
| Jun 15, 2026 | 14.50 | 14.79 | 14.15 | 14.33 | 84.3K |
| Jun 12, 2026 | 14.81 | 14.91 | 14.47 | 14.63 | 44.18K |
| Jun 11, 2026 | 14.18 | 14.94 | 14.00 | 14.69 | 59.8K |
| Jun 10, 2026 | 14.05 | 14.76 | 14.04 | 14.15 | 129.32K |
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
| Employees | 120 |
| Beta | 0.15 |
| Sales or Revenue | $31.79M |
| 5Y Sales Change% | -0.027% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Devices |